HOME >> BIOLOGY >> NEWS
Society of Nuclear Medicine to offer first $25,000 Mallinckrodt Seed Grant

e considered until a satisfactory summary of an earlier grant is received.

This grant may supplement--not duplicate--other financial support. It will not pay institutional overhead costs or indirect costs, and no salary support will be provided for a principal investigator or co-principal investigators. The grant will be limited to a time span of one year, and no extensions will be allowed. Grantees are expected to submit results of the research as an abstract for presentation at SNM's Annual Meeting and/or as a scientific manuscript to the Journal of Nuclear Medicine.

SNM's grants and awards program is funded by both the Education and Research Foundation for the Society of Nuclear Medicine and the SNM Technologist Section (SNMTS) Professional Development and Education Fund. This program provides research grants and fellowships, educational scholarships and recognition awards to researchers, young investigators and students in nuclear medicine, molecular imaging and nuclear medicine technology. The Education and Research Foundation for SNM has been supporting the molecular imaging/nuclear medicine community since its founding in 1969. The foundation's mission is to advance excellence in health care through education and research in molecular imaging/nuclear medicine by provision of grants and awards.

"Providing molecular imaging/nuclear medicine professionals with increased support for cutting-edge research is one of the major priorities of SNM and the foundation," said ERF President Michael D. Devous Sr., Ph.D. "We are thankful that Tyco Healthcare/Mallinckrodt came forward to help us on this venture," he added.

For more information about this grant and application materials or to learn more about SNM, the foundation or making a contribution, please contact Kathy Bates, SNM's director of development, via phone at 703-708-9000, ext. 1028, or via e-mail at kbates@snm.org. Information is poste
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-708-9000
Society of Nuclear Medicine
13-Apr-2005


Page: 1 2 3

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. American Chemical Society meets Aug. 19-23 in Boston
3. American Chemical Societys Weekly PressPac -- Aug. 1, 2007
4. American Chemical Societys Weekly PressPac -- July 25, 2007
5. American Chemical Societys Weekly PressPac -- July 18, 2007
6. American Chemical Societys Weekly PressPac -- July 11, 2007
7. Tips from the Journals of the American Society for Microbiology
8. American Chemical Societys Weekly PressPac -- June 27/July 3, 2007
9. Health Physics Society
10. American Chemical Societys Weekly PressPac -- June 20, 2007
11. WPI professor to represent American Mathematical Society at exhibition on science funding

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Society Nuclear Medicine offer first Mallinckrodt Seed Grant

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: